Platelet-rich plasma is not a single standardized biologic. Blood collection, preparation method, cellular composition, final volume, platelet dose, activation, and delivery can vary between PRP treatments. Consensus reporting frameworks have therefore emphasized describing how PRP is prepared, characterized, and administered. 1
A procedure note that records only “PRP injected” identifies the treatment category, but how much does it tell you about the biologic that was actually prepared and delivered?
Right knee PRP injection performed under ultrasound guidance. 5 mL PRP injected. Patient tolerated the procedure well.
30 mL whole blood processed using [PRP system/protocol]. Final PRP volume 5.0 mL. Baseline platelet count 250 × 106/mL. Final platelet concentration 1,250 × 106/mL. Total platelet dose 6.25 × 109. [Leukocyte/RBC characteristics when known]. Ultrasound-guided injection to [target].
A PRP procedure involves both a clinical procedure and preparation of an autologous biologic product. Documenting the treatment site, injection target, approach, guidance, volume, and patient response describes the procedure. Understanding the PRP itself may require additional information about collection, processing, composition, volume, and delivery.
The Minimum Information for Studies Evaluating Biologics in Orthopaedics, or MIBO, consensus statement was developed because inadequate reporting of PRP preparation, characterization, and delivery limited the interpretation and reproducibility of clinical research. The final PRP checklist contains 23 reporting statements derived through expert consensus. 1
Reporting remains incomplete even after publication of MIBO. A 2026 systematic review of PRP-augmented ACL reconstruction studies found mean adherence of 50.1% among studies published after MIBO, with platelet recovery and final PRP analysis among the poorly reported elements. 2
Clinical question: If two treatments are both documented simply as “PRP,” can the medical record tell you whether the biologics were actually comparable?
Not every possible variable needs to appear in every note. A more useful approach is to separate PRP documentation into three layers: the clinical procedure, product traceability, and biologic characterization.
A multidisciplinary PRP safety initiative at Vanderbilt University Medical Center evaluated workflows across specialties and identified variability in PRP preparation, labeling, injection practices, and documentation. The resulting recommendations addressed electronic medical record documentation for medication use, kit components and expiration date, phlebotomy, and the PRP product following centrifugation. 3
The authors also discussed capturing relevant lot numbers, expiration dates, and personnel involved in collection and administration within their institutional regulatory framework. Implementation required collaboration with healthcare technology teams because procedure documentation templates varied by clinic, PRP application, and kit. 3
Platelet concentration describes the number of platelets within a given volume of PRP. Total platelet dose incorporates both concentration and volume. The DEPA classification proposed total injected platelet dose as a central PRP characterization variable. 4
In the original DEPA analysis, calculated platelet doses varied markedly among evaluated preparation systems, illustrating why concentration alone does not fully describe the amount of platelets delivered. 4
Not every clinical PRP workflow includes baseline or final cellular analysis. A procedure note can still document preparation and delivery variables that are actually known without substituting population averages, manufacturer averages, or published performance data for patient-specific measurements.
Published device performance, population platelet averages, or historical practice data may provide context, but they should not be presented in the medical record as though they were measured in the individual patient.
A useful PRP procedure note does not require the clinician to replace the practice's existing electronic health record. Structured documentation can instead be designed for incorporation into the workflow already used by the clinic or health system.
Generate structured text and paste it into the appropriate procedure-note field.
Use a standardized PRP documentation structure within the EHR's existing template tools.
Generate a finalized document for incorporation into the medical record when appropriate.
Different clinics document different levels of PRP detail. A customizable procedure note can allow clinicians to include the sections relevant to their workflow and remove those they do not use.
Procedure, indication, preparation basics, administration, and tolerance.
Add traceability, processing details, medications, and additional procedural variables.
Add baseline and final laboratory data, platelet recovery, and total platelet dose when available.
Build a customizable PRP procedure note around the way your practice actually works. Save reusable PRP workflows and note templates, document PRP characterization when available, and generate clean documentation for your existing medical record workflow.
Include the documentation elements your practice uses and remove the sections that do not belong in your procedure note.
Save preferred PRP systems, preparation methods, documentation fields, and reusable procedure-note configurations.
Add baseline platelet count, final concentration, injected volume, platelet dose, and cellular composition when those measurements are available.
Produce consistent documentation designed for incorporation into your practice's existing EMR or EHR workflow.
The workflow is designed so patient-identifying information does not need to be stored in PRPdose.
PRPdose provides educational and documentation-support tools for clinicians. Clinical judgment and applicable institutional, regulatory, legal, and payer requirements remain controlling.
References below are provided so clinicians can review the underlying literature directly. Several sources address research reporting or institutional safety workflows rather than universal clinical documentation requirements. They are cited for the specific principles described above.
Expert Delphi consensus establishing minimum reporting requirements for clinical studies evaluating PRP and mesenchymal stem cells.
Systematic review of 26 PRP-augmented ACL reconstruction studies. Mean MIBO adherence was 50.1% after publication of the guideline, with final PRP analysis and platelet recovery among the poorly reported elements.
Multidisciplinary PRP safety initiative addressing labeling, medication safety, kit components, expiration dates, phlebotomy, PRP product documentation, and EMR workflow.
Introduced Dose, Efficiency, Purity, and Activation as PRP characterization dimensions and incorporated total injected platelet dose into PRP classification.
Additional recent evidence that incomplete PRP reporting remains a persistent problem across clinical literature.